Email Facebook Twitter

London South East Natural Resources Briefing webcast: #Emmerson #Alba #Condor Gold #Gold analysis
Angus Energy in talks to buy 'transformational' gas asset in North England

ShareCast News

Roche's 'Tecentriq' gets another FDA approval

Fri, 7th Dec 2018 10:40

(Sharecast News) - Roche announced on Friday that the US Food and Drug Administration (FDA) approved 'Tecentriq' (atezolizumab) in combination with 'Avastin' (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumour aberrations.

The Swiss drugmaker said the approval was based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with Avastin and chemotherapy helped people live "significantly longer", compared to Avastin and chemotherapy in the 'intention-to-treat wild-type' (ITT-WT) population.

It said the safety profile of the Tecentriq combination was consistent with that observed in previous studies.

Roche said it was working with the FDA on post-marketing commitments to better understand and characterise the potential effects of Tecentriq-related anti-drug antibodies and neutralising antibodies across all of its studies.

An analysis of anti-drug antibodies in the IMpower150 study showed no impact on the efficacy of Tecentriq.

Tecentriq was also approved by the FDA to treat people with metastatic NSCLC who had disease progression during or following platinum-containing chemotherapy, and had progressed on an appropriate FDA-approved targeted therapy if their tumour had EGFR or ALK genetic alterations.

"This Tecentriq regimen has demonstrated a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer," said Roche's chief medical officer and head of global product development, Sandra Horning.

"Today's approval supports our combination approach for Tecentriq in lung cancer and our vision to develop medicines that improve outcomes for patients with this complex disease."

Back to ShareCast News

Share Price, Share Chat, Stock Market news at
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.